Anti-monkeypox Drug Discovery Solutions
Online inquiry

We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.

* Name
* Phone
* Email
* Products or Services Interested
Project Description

Anti-monkeypox Drug Discovery Services Targeting Cellular Target

Monkeypox is a rare disease caused by monkeypox virus infection. In recent years, the monkeypox disease has concentrated and spread rapidly. Based on our extensive experience and advanced platforms, now Creative Biolabs provides anti-monkeypox drug discovery services targeting cellular targets for our clients all over the world.

Overview of Monkeypox virus (MPXV)

Monkeypox virus (MPXV) is an enveloped double-stranded DNA virus that can be divided into the central African clade and the West African clade. The MPXV has a genome size of about 190kb and encodes more than 200 proteins. Together with Variola virus (VARV) and Cowpox virus, MPXV is a member of the genus Orthopoxvirus (OPXVs). Poxviruses produce two types of infectious virus particles during the replication stage, namely intracellular mature virus (IMV) and extracellular enveloped virus (EEV). The life cycle of poxvirus replication can be divided into the following stages: entry and uncoating, early transcription, viral DNA replication, late transcription, viral particle assembly, and release.

Unlike general RNA viruses, MPXV is a relatively large DNA virus with the ability to self-detect and repair mutations, so the probability of mutation is relatively small. Studies have shown that there are only 94 nucleotide changes and 51 amino acid changes compared to the original MPXV genome.

Poxviridae replication cycle.Figure.1 Poxviridae replication cycle.

Cellular Targets of Monkeypox virus (MPXV)

With the in-depth understanding of the structure and replication cycle of monkeypox, it is found that functional proteins and the related gene products during the replication process may become novel targets for anti-monkeypox drug development. In recent years, a large number of compounds with inhibitory activity against poxviruses have been reported. However, there are still problems existing such as low activity, high cytotoxicity, and poor solubility. To overcome these limitations, it is necessary to identify and validate some more promising targets. Subsequently, more novel poxvirus inhibitors can be discovered through a series of strategies such as prodrug strategy, drug repurposing, high-throughput screening, virtual screening, and phenotype screening.

At present, many potential targets and corresponding inhibitors have been discovered, which are expected to be developed into new anti-poxvirus infection drugs.

Features of our Anti-Monkeypox Drug Discovery Services

  • Advanced platforms to ensure the best achievement for every single step.
  • Fully customizable experimental design to expand beyond standard procedure.
  • Competitive price with the best quality.
  • Reliable lab report with timely updates.

Creative Biolabs is a leading service provider that focuses on anti-monkeypox drug development. We can assist you in designing the best research outline customized to meet the requirements of clients’ programs. If you are interested in our services and products, please do not hesitate to contact us for more details.

Related Products

We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.